We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Tissue Regenix Group Plc | LSE:TRX | London | Ordinary Share | GB00BNTXR104 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 61.50 | 61.00 | 62.00 | 61.50 | 61.50 | 61.50 | 58,537 | 08:00:21 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 29.49M | -302k | -0.0043 | -143.02 | 43.4M |
TIDMTRX
RNS Number : 6788F
Tissue Regenix Group PLC
19 May 2017
Tissue Regenix Group plc
Potential Acquisition
Leeds, 19 May 2017 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group") the regenerative medical devices company, notes the recent application for a temporary restraining order ("TRO") filed by one of the members of CellRight Technologies, LLC ("CellRight") with Bexar County District Court against CellRight, a US regenerative medicine business based in San Antonio, Texas, in relation to a potential sale of CellRight to Tissue Regenix. Tissue Regenix confirms that it is in discussions with CellRight regarding a possible acquisition of CellRight by Tissue Regenix.
There can be no certainty at this stage that the discussions between the Group and CellRight will lead to an acquisition.
A further announcement will be made when appropriate.
This announcement contains inside information.
For more Information:
FTI Consulting Tel: 020 Brett Pollard/ Mo Noonan 3727 1000 ========================================== =========== Jefferies International Ltd Tel: 020 Simon Hardy / Harry Nicholas 7029 8000 Tissue Regenix Group Tel: 0330 Caitlin Pearson Corporate Communications 430 3073 Director ========================================== ===========
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL(R)') technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient's body which can then be used to repair diseased or worn out body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.
Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds. The company commercialises academic research conducted by our partners around the World.
In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - 'Tissue Regenix Wound Care Inc.', as part of its commercialisation strategy for its dCELL(R) technology platform.
This information is provided by RNS
The company news service from the London Stock Exchange
END
ACQUKORRBRAVAAR
(END) Dow Jones Newswires
May 19, 2017 06:35 ET (10:35 GMT)
1 Year Tissue Regenix Chart |
1 Month Tissue Regenix Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions